Rapid Therapeutic Company Management Evaluation
| RTSL Stock | USD 0 0.00 0.00% |
Rapid Therapeutic employs about 8 people. The company is managed by 6 executives with a total tenure of roughly 19 years, averaging almost 3.0 years of service per executive, having 1.33 employees per reported executive. Inspection of Rapid Therapeutic's management performance can provide insight into the company performance.
| Donal Schmidt Insider CEO Pres |
| Duane Drinkwine Insider Chief Officer |
Rapid |
Rapid Therapeutic Management Team Effectiveness
The company has return on total asset (ROA) of (0.554) % which means that it has lost $0.554 on every $100 spent on assets. This is way below average. Rapid Therapeutic's management efficiency ratios could be used to measure how well Rapid Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities.Rapid Therapeutic Workforce Comparison
Rapid Therapeutic Science is currently regarded as top stock in number of employees category among its peers. The total workforce of Medical Devices industry is at this time estimated at about 31.0. Rapid Therapeutic totals roughly 8.0 in number of employees claiming about 26% of all equities under Medical Devices industry.
Rapid Therapeutic Science Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Rapid Therapeutic Science Price Series Summation is a cross summation of Rapid Therapeutic price series and its benchmark/peer.
Rapid Therapeutic Notable Stakeholders
A Rapid Therapeutic stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Rapid Therapeutic often face trade-offs trying to please all of them. Rapid Therapeutic's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Rapid Therapeutic's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Donal Schmidt | CEO Pres | Profile | |
| Duane Drinkwine | Chief Officer | Profile | |
| Hughes Watler | CFO Director | Profile | |
| Sean Berrier | VP | Profile | |
| Frank Gill | Chief Technician | Profile | |
| Ryan Johnson | VP Marketing | Profile |
About Rapid Therapeutic Management Performance
The success or failure of an entity such as Rapid Therapeutic Science often depends on how effective the management is. Rapid Therapeutic management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Rapid management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Rapid management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc. Rapid Therapeutic operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 8 people.
Rapid Therapeutic Workforce Analysis
Traditionally, organizations such as Rapid Therapeutic use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Rapid Therapeutic within its industry.Rapid Therapeutic Manpower Efficiency
Return on Rapid Therapeutic Manpower
| Revenue Per Employee | 66.75 | |
| Revenue Per Executive | 89.0 | |
| Net Loss Per Employee | 358.5K | |
| Net Loss Per Executive | 478K |
Other Information on Investing in Rapid Pink Sheet
Rapid Therapeutic financial ratios help investors to determine whether Rapid Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rapid with respect to the benefits of owning Rapid Therapeutic security.